secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0000939767-22-000096
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis Q2 2022 revenue $419.4M, cabozantinib net product revenue $347M, GAAP EPS $0.22
--------------------------------------------------------------------------------

- Total revenues $419.4M, up from $385.2M in Q2 2021; cabozantinib franchise net product revenue $347.0M, up 22% YoY.
- GAAP net income $70.7M ($0.22 diluted EPS) vs $96.1M ($0.30) in Q2 2021; non-GAAP EPS $0.28.
- Cash and investments $2.0B at June 30, 2022, up from $1.9B at year-end 2021.
- Positive PFS data for COSMIC-313; initiated STELLAR-303 phase 3 for XL092 and phase 1 for XL114.
- Signed business development agreements with BioInvent and Ryvu Therapeutics to expand biologics capabilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976722000096/0000939767-22-000096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976722000096/exel-20220809.htm
  HTML page:      https://secwatch.observer/filing/0000939767-22-000096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer